š Executive Summary
The 2023-2025 era has witnessed a paradigm shift toward "stacked" pharmacological interventions and precision neuromodulation. Up to 50% of patients fail to achieve remission with first-line antidepressants. The probability of remission drops precipitously with each failed trial. Modern algorithms prioritize augmentation over serial switching and integrate device-based therapies (TMS, VNS) earlier in the treatment trajectory.
šÆ Depression Staging Models
| Stage |
Definition |
Clinical Action |
| I | Failure of 1 adequate trial | Optimize dose/duration; assess adherence |
| II (TRD) | Failure of 2 trials (different classes) | Augment vs Switch; consider TMS |
| III | Failure of augmentation | Combination therapy; neuromodulation |
| IV | Failure of neuromodulation | VNS; ECT |
| V | Failure of ECT | DBS, MST, FUS; clinical trials |
Difficult-to-Treat Depression (DTD): Emerging concept framing TRD as chronic disease requiring management vs cureāreframes therapeutic goals toward functional recovery.
š Augmentation Strategies
Lithium Augmentation
- Evidence: OR 2.34-3.31; NNT ~5
- Anti-suicidal: 60-70% reduction in suicidal death vs placebo
- Target level: 0.4-0.8 mEq/L (lower than bipolar maintenance)
- Monitoring: eGFR/TSH every 3-6 months
Atypical Antipsychotics
| Agent |
Mechanism |
Best For |
| Aripiprazole | D2 partial agonist | Anhedonia, activation |
| Quetiapine XR | NRI via norquetiapine | Anxious depression, insomnia |
| Brexpiprazole | D2 partial (lower intrinsic activity) | Akathisia sensitivity |
"California Rocket Fuel"
Venlafaxine + Mirtazapine: SNRI + NaSSA combination targeting multiple monoamine systems. Mirtazapine's 5-HT2/3 blockade directs serotonin to 5-HT1A while mitigating GI/sexual side effects. Consider for deep resistance (Stage III).
š§ Neuromodulation Options
Transcranial Magnetic Stimulation (TMS)
| Protocol |
Duration |
Remission Rate |
| Standard 10Hz rTMS | 4-6 weeks | ~30% |
| iTBS | 4-6 weeks (3 min/session) | ~30-50% |
| SAINT/SNT | 5 days (10 sessions/day) | ~79% |
SAINT Protocol Details
- FDA cleared: 2022/2024 for TRD
- Targeting: fcMRI-guided DLPFC to sgACC anticorrelation
- Dose: 50 sessions in 5 days (10/day with 50-min intervals)
Other Neuromodulation
- ECT: Ultrabrief pulse RUL preferredāpreserves cognition, may need more sessions
- VNS: For chronic maintenance; requires ā„4 failed trials; slow onset (6-12 months)
- MST: Magnetic seizureāsimilar efficacy to ECT, superior cognitive safety
- FUS: Low-intensity focused ultrasoundāemerging, non-invasive DBS alternative
ā ļø Critical Safety: Switching Protocols
MAOI Washout: Fatal serotonin toxicity risk. Fluoxetine requires 5-week washout before starting MAOI due to norfluoxetine metabolite (tĀ½ 7-15 days). Irreversible MAOIs require 2-week washout before starting serotonergic agents.
Cross-Tapering Schedule (SSRI to NaSSA)
| Week |
SSRI (e.g., Citalopram) |
Mirtazapine |
| 1 | 50% dose | 15 mg |
| 2 | 25% dose | 30 mg |
| 3 | Minimal dose | 30 mg |
| 4 | Discontinue | Optimize 30-45 mg |